Rare diseases
Investigational molecules
Locations
1000 Sierra Point Pky, 94005, United States
Myokardia Inc. focuses on clinical research in hypertrophic cardiomyopathy, with particular attention to symptomatic obstructive hypertrophic cardiomyopathy and left ventricular outflow tract obstruction. The funded studies examine cardiac symptoms, physical limitation, and exercise capacity in affected adults.
Research activity also includes imaging-based evaluation of cardiac structure and myocardial thickness in relation to disease burden.
Myokardia Inc. runs clinical trials in conditions such as Hypertrophic cardiomyopathy, Non-obstructive cardiomyopathy, Dilated cardiomyopathy, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
Study on Mavacamten for Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
AustriaStudy on the Effects of MYK-224 for Patients with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
ItalyStudy on Mavacamten for Adults with Non-obstructive Hypertrophic Cardiomyopathy
AustriaLong-term Safety Study of Mavacamten for Adults with Hypertrophic Cardiomyopathy from Previous Trials
BelgiumStudy on Danicamtiv for Patients with Primary Dilated Cardiomyopathy Due to MYH7 or TTN Gene Variants
GermanyIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
